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Original Clinical Science—Liver

Survival After Liver Transplantation: An
International Comparison Between the United
States and the United Kingdom in the Years
2008–2016
Tommy Ivanics, MD,1,2 David Wallace, MSc,3,4 Phillipe Abreu, MD, PhD,1 Marco PAW Claasen, MD,1,5
Chris Callaghan, PhD,4 Thomas Cowling, PhD,6 Kate Walker, PhD,3 Nigel Heaton, MB, FRCS,6 Neil Mehta,
MD,7 Gonzalo Sapisochin, MD, PhD,1 and Jan van der Meulen, PhD3

Background. Compared with the United States, risk-adjusted mortality in the United Kingdom has historically been worse
in the first 90 d following liver transplantation (LT) and better thereafter. In the last decade, there has been considerable
change in the practice of LT internationally, but no contemporary large-scale international comparison of posttransplant outcomes has been conducted. This study aimed to determine disease-specific short- and long-term mortality of LT recipients
in the United States and the United Kingdom. Methods. This retrospective international multicenter cohort study analyzed
adult (≥18 y) first-time LT recipients between January 2, 2008, and December 31, 2016, using the Organ Procurement and
Transplantation Network/United Network for Organ Sharing and the UK Transplant Registry databases. Time-dependent
Cox regression estimated hazard ratios (HRs) comparing disease-specific risk-adjusted mortality in the first 90 d post-LT,
between 90 d and 1 y, and between 1 and 5 y. Results. Forty-two thousand eight hundred seventy-four US and 4950
UK LT recipients were included. The main LT indications in the United States and the United Kingdom were hepatocellular carcinoma (25.4% and 24.9%, respectively) and alcohol-related liver disease (20.3% and 27.1%, respectively). There
were no differences in mortality during the first 90 d post-LT (reference: United States; HR, 0.96; 95% confidence interval
[CI], 0.82–1.12). However, between 90 d and 1 y (HR, 0.71; 95% CI, 0.59–0.85) and 1 and 5 y (HR, 0.71; 95% CI, 0.63–
0.81]) the United Kingdom had lower mortality. The mortality differences between 1 and 5 y were most marked in hepatocellular carcinoma (HR, 0.71; 95% CI, 0.58–0.88) and alcohol-related liver disease patients (HR, 0.64; 95% CI, 0.45–0.89).
Conclusions. Risk-adjusted mortality in the United States and the United Kingdom was similar in the first 90 d post-LT
but better in the United Kingdom thereafter. International comparisons of LT may highlight differences in healthcare delivery
and help benchmarking by identifying modifiable factors that can facilitate improved global outcomes in LT.

(Transplantation 2021;00: 00–00).
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INTRODUCTION
International comparisons of surgical mortality offer insight
into the disparities in access to and delivery of surgical treatments.1–6 Based on such comparisons, reappraising national
healthcare practices can afford opportunities for policy and
practice change that have, in the past, translated into population-level improvements in postoperative outcomes.1,2
Inevitably, many factors drive outcomes following surgery, and many of these are not readily measurable.1,2,5
This makes benchmarking international variations in surgical outcomes challenging.4 However, in contrast to other
surgical specialties, the standardized nature of liver transplantation (LT) practice makes it well placed for undertaking reliable international comparisons of surgical mortality.1
Unfortunately, difficulties in obtaining, combining, and
analyzing data sets from different countries mean very few
reports describing comparisons of LT outcomes exist.1
In the only previous comparison between the United States
and the United Kingdom, posttransplant mortality in
47 791 LT recipients between 1994 and 2005 was significantly worse in the United Kingdom in the first 90 d after
surgery and then better thereafter.1 However, more than a
decade on, further time-dependent analysis by our international collaboration has identified that there have been
era-specific improvements in both the short- and long-term
outcomes of recipients who received an LT in the United
Kingdom.6 Consequently, a contemporary evaluation is
warranted.
Given that international comparisons of healthcare outcomes enable policymakers and clinicians to identify areas
of healthcare delivery where countries could learn from
each other and that era-specific improvement in posttransplant mortality have been observed,1–5 we used a uniquely
harmonized combined data set to carry out a disease-specific time-dependent comparison of short- and long-term
patient mortality following LT in the United Kingdom and
the United States between 2008 and 2016.
MATERIALS AND METHODS
Databases

The UK Transplant Registry and the Organ Procurement
and Transplantation Network (OPTN)/United Network
for Organ Sharing (UNOS) data set were used for this
analysis. Descriptions of these databases and evidence of
their completeness, accuracy, and reliability have been
published elsewhere.1,5,6
The study population included all patients aged 18 y or
older who received a first-time elective LT in the 2 countries between January 1, 2008, and December 31, 2016
(Figure 1). The study’s start date was chosen to coincide
with the introduction in the United Kingdom in 2008 of
organ offering policies based on predicted waiting list
mortality. In the same time period in the United States,
the Model for End-Stage Liver Disease (MELD) scorebased allocation, the Share 15 and Share 35 scheme, and
the MELD-Sodium allocation system were introduced.7–9
Patients who underwent LT for liver cancer types other than
hepatocellular carcinoma (HCC) and those who underwent
multivisceral, super-urgent, domino, living-related LTs or
were transplanted for acute liver failure were excluded. We
also excluded patients whose survival data were missing.
This study received ethics approval after review from the

National Health Service Health Research Authority (IRAS
project ID: 218152; CAG reference 17/CAG/0025).
Data Management

The UK Transplant Registry and OPTN/UNOS data sets
were harmonized to ensure that liver disease classification
and risk factor definitions were comparable.1 Patients were
grouped according to a liver disease classification system
(Table S1, SDC, http://links.lww.com/TP/C303) that was
first adopted by Roberts et al.1,10 In the event of multiple
diagnoses, patients were assigned to the diagnosis most
likely to have influenced their prognosis at the time of transplantation.1,10 Disease classification was undertaken in a
hierarchical order: cancer, hepatitis C virus (HCV) cirrhosis,
primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), alcohol-related liver disease (ALD), autoimmune disease (AID), metabolic, and others.1,10 For example,
patients with a coded diagnosis of HCV cirrhosis and a
free text diagnosis of HCC were assigned to the HCC category.1,10 All patients with Wilson disease and Budd-Chiari
syndrome were assigned to the metabolic and other liver
diseases categories, respectively, regardless of the mode of
their disease presentation.1,10 Transplant center volume was
defined as the average number of first-adult single organ
LTs, excluding multivisceral and retransplants, performed
during the study period at a given center per year.1
For multivariable analyses, creatinine was set to 4.0 mg/
dL for those with lower values who received renal replacement therapies immediately before transplantation.1
Implausible values of body mass index (BMI; <10 or
>100 kg/m2), cold ischemic time (CIT; >40 h), serum bilirubin (<0.1 mg/dL), serum creatinine (<0.1 or >15 mg/dL),
and serum albumin (<0.7 or >6.0 g/dL) were considered
to be missing.1 The MELD score (calculated using serum
creatinine, total serum bilirubin, and international normalized ratio) was used to score the recipients’ severity of
the liver disease in both the United States and the United
Kingdom.11 Ascites and encephalopathy were considered
as dichotomous variables. Recipients’ functional status
at the time of transplantation was assessed using a modified 3-point scale ranging from “able to carry out normal
activity without restriction—high functional status” to
“intermediate functional status” and “completely reliant
on care—low functional status.”12–14 Values for ethnicity were categorized into White and non-White groups.
Donor quality was measured using the Feng Donor Risk
Index (DRI) (derived from donor age, sex, height, type
[donation after circulatory death donor (DCD) or not],
serum bilirubin, smoking history, and whether the liver
was split, with larger values representing poorer donor
livers).15 The DRI was included as a variable as it was
developed using UNOS data and has subsequently been
validated for the Eurotransplant region, where transplant
data from the United Kingdom are included.16,17 CIT was
defined as the duration between the start of cold perfusion
in the donor to the start of blood flow through the organ
in the recipient.18 In the United States, UNOS/OPTN collects information on death at 6 and 12 mo intervals and
validates their data with information from the Centers for
Medicare and Medicaid Services and the National Death
Index.19 UNOS links the OPTN data to the Social Security
Death Master File to augment ascertainment of candidate
and recipient death, and hence does not solely rely on
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FIGURE 1. Flowchart detailing selection of study population (2008–2016). UK, United Kingdom; US, United States.

individual transplant center reporting as this would lead to
inaccuracies if the patients does not continue their followup at their original transplant center.19–21 Death ascertainment in the United Kingdom is closely monitored through
center-specific 3-mo follow-up forms submitted centrally
to National Health Service Blood and Transplant.
Statistical Analyses

Categorical variables were presented as proportions and
compared using chi-square tests, and continuous variables
were presented as means with SDs. Patients transplanted
for non-HCC indications who were subsequently found

to have HCC on explant pathology were analyzed on an
intention-to-treat basis and remained in the non-HCC
cohorts.
The Kaplan-Meier method was used to compare liver
disease-specific patient mortality between the different countries (United Kingdom versus United States).
Follow-up data were available until April 7, 2017.
The median follow-up time for the United States was
944 d (interquartile range, 346–1820) and for the United
Kingdom 1011 d (interquartile range, 370–1796).
Cox regression analysis was used to estimate overall and
disease-specific hazard ratios (HRs) indicating the relative

Copyright © 2021 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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difference in risk of death in the United States versus the
United Kingdom in the following periods after LT (“epochs”):
the first 90 d, 90 d to 1 y, and beyond the first year. The United
States was used as the baseline value with an HR <1, indicating mortality to be higher in the United States compared
with the United Kingdom. The analysis was censored at 5 y
posttransplantation. Only those clinically plausible recipient
and donor risk factors recorded to a comparable degree in
both databases with missing values in <10% of the patients
were included in the risk-adjusted regression models.1 These
included recipient characteristics: sex, age, ethnicity, BMI (kg/
m2), disease cause, functional status, ascites, encephalopathy, HCV status, MELD, pretransplant renal replacement
therapy, previous abdominal surgery, and donor characteristics: sex, age, BMI (kg/m2), CIT, donor type (DCD/donation after brainstem death), cause of death, ABO match, and
graft type. A similar analysis, as for patient survival including
risk adjustments for the above-mentioned variables, was performed to investigate risk of graft loss. Adjustment for specific tumor characteristics was not included as comparisons
of posttransplantation mortality in HCC patients were made
with a cohort of non-HCC patients.22 Interaction terms were
included in the Cox regression models to determine whether

the HRs for overall mortality and disease-specific comparison of mortality differed according to the epoch of follow-up
time. A sensitivity analysis was performed to assess the impact
of the era of transplantation (2008–2011 and 2021–2016).
The significance of the interaction term was tested using a
global Wald test.
Missing donor and recipient characteristics were
imputed using chained equations, creating 10 complete
data sets with regression results pooled using Rubin’s
rules.23 Stata V15 (StataCorp, College Station, TX) was
used for all statistical analyses. A P < 0.05 was considered
to indicate a statistically significant result.
RESULTS
Clinical Characteristics

Between January 1, 2008, and December 31, 2016,
42 874 adults received a first single organ LT in 134 centers
in the United States, whereas 4950 such transplants were
performed in 7 centers in the United Kingdom (Table 1).
Compared with recipients in the United Kingdom, LT
recipients in the United States were less likely to receive
livers from older and from male donors (Table 1). US

TABLE 1.

Donor and recipient characteristics according to country
Country
United States
United States
(n = 42 874)

Characteristics

Donor
Female
Age, mean (SD), y
BMI, mean (SD), kg/m2
Trauma as cause of death
DCD donors
Segmental graft type
CIT, mean (SD), min
ABO match—identical
DRI, mean (SD)
Recipient
Female
Age, mean (SD), y
Non-White ethnicity
HCC indication for transplant
BMI, mean (SD), kg/m2
MELD,a mean (SD)
Waiting list time (d)
Blood group O
Dependent functional status level 3b
Ascites
Encephalopathy
Presence of anti-HCV antibodies
Renal replacement before LT
Previous abdominal surgery
Transplant center volume

United Kingdom
Missing,
% (n)

United Kingdom
(n = 4950)

Missing,
% (n)

59.5% (25 529)
42.1 (16.6)
27.8 (6.4)
32.5% (13 654)
5.8% (2502)
1.3% (555)
378 (167)
94.5% (40 522)
1.44 (0.28)

0.0% (0)
0.0% (0)
0.1% (52)
2.1% (902)
0.04% (17)
0.0% (0)
0.8% (354)
0.0% (0)
0.0% (0)

46.2% (2289)
49.3 (16.0)
26.4 (4.9)
8.0% (396)
24.0% (1188)
8.1% (399)
517 (163)
98.5% (4874)
1.72 (0.40)

0.0% (0)
0.0% (0)
0.2% (10)
0.0% (0)
0.0% (0)
0.0% (0)
8.0% (400)
0.0% (0)
1.7% (84)

<0.001
0.02
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

31.5% (13 523)
55.6 (9.6)
28.4% (12 158)
29.3% (12 550)
28.7 (5.7)
21.7 (10.7)
278.8 (515.6)
44.9% (19 239)
21.9% (9270)
74.4% (31 910)
61.5% (26 363)
42.9% (16 974)
9.2% (3947)
44.2% (18 691)
62.7 (32.7)

0.002% (1)
0.0% (0)
0.0% (0)
0.0% (0)
0.02% (9)
0.1% (45)
0.0% (0)
0.0% (0)
1.2% (510)
0.0% (0)
0.0% (0)
2.0% (844)
0.0% (0)
1.3% (541)
0.0% (0)

32.8% (1622)
53.0 (11.2)
12.5% (618)
25.8% (1276)
27.3 (5.2)
16.5 (6.7)
152.3 (189.3)
41.3% (2045)
14.1% (690)
53.6% (2643)
31.0% (1510)
18.1% (679)
4.9% (242)
11.8% (582)
92.5 (32.3)

0.0% (0)
0.0% (0)
0.04% (2)
0.0% (0)
0.1% (5)
0.7% (36)
0.0% (0)
0.0% (0)
1.3% (64)
0.3% (17)
1.7% (83)
0.4% (21)
0.3% (13)
0.4% (18)
0.0% (0)

0.08
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

P

All data are expressed as percentage (number of patients), unless otherwise specified.
a
United States Model for End-Stage Liver Disease.
b
Level 3 of a 3-point modified scale of functional status (including ECOG from United Kingdom and Karnofsky from United States).
BMI, body mass index; CIT, cold ischemia time; DCD, donation after circulatory death; DRI, donor risk index; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; HCV, hepatitis
C virus; LT, liver transplantation; MELD, Model for End-Stage Liver Disease.
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recipients were also much less likely to receive livers
donated following circulatory death (DCD) but more
likely to receive livers donated from those who had died
following trauma. CIT in the United States was significantly lower as was the mean DRI.
The differences in age, sex, and BMI distributions of
recipients from the 2 countries were small, although the
differences in mean age and BMI were statistically significant (Table 1). Patients in the United States waited a
markedly longer time to receive their LT and were more
often from a non-White ethnic background and more
often found to have anti-HCV antibodies. At the time
of transplantation, patients in the United States also had
more evidence of severe liver disease (mean MELD [SD]
United States 21.7 [10.7] versus United Kingdom 16.5
[6.7]) and were more likely to show the clinical sequelae of end-stage liver disease (ascites [%]; United States
74.4% versus United Kingdom 53.6%; encephalopathy
[%], United States 61.5% versus United Kingdom 31.0%).
They were also more likely to require renal support before
their transplant or to have had previous abdominal surgery (Table 1). Mean annual transplant volume was found
to be lower in the United States compared with the United
Kingdom (62.7 [32.7] versus 92.5 [32.3], respectively,
P < 0.001).

5

United States, ALD accounted for a lower proportion of all
LTs than it did in the United Kingdom, whereas for metabolic liver disease and HCV, the reverse was true. The frequency of HCV as an indication for transplant was found
to decrease markedly in both countries. In contrast, the
proportion of patients transplanted for AID, PSC, and PBC
remained relatively static in both the United States and the
United Kingdom (Figure 2 and Table S2, SDC, http://links.
lww.com/TP/C303).
Posttransplant Mortality

Five years after transplantation, overall survival in the
United States was poorer than that observed in the United
Kingdom (75.6% [95% CI, 75.1%-76.1%] and 81.9%
[95% CI, 80.5%-83.3%], P < 0.001, respectively; Figure 3)
with this pattern of results also reflected in many of the disease-specific comparisons of posttransplantation outcome,
including in those patients transplanted for HCC (P = 0.04),
HCV (P = 0.001), PBC (P = 0.003), ALD (P < 0.001), AID
(P = 0.01), and metabolic liver disease (P = 0.01) (Figure 3
and Figure S1, SDC, http://links.lww.com/TP/C303).
In contrast, no statistically significant difference in mortality at 5 y was observed for those transplanted with PSC
(P = 0.48), HBV (P = 0.27), and the heterogeneous set of
liver diseases classified as “other” (P = 0.38) (Figure S1,
SDC, http://links.lww.com/TP/C303).

Indications for Liver Transplant

In the United States and the United Kingdom, the most
common indications for LT were HCC and ALD, which
together accounted in both countries for approximately
one-half of all first-time LTs (Figure 2 and Table S2,
SDC, http://links.lww.com/TP/C303). Toward the end of
the study period, the rate of transplantation for ALD in
both countries was also increasing as it was in those who
were transplanted for metabolic liver disease (Figure 2
and Table S2, SDC, http://links.lww.com/TP/C303). In the

Risk-adjusted Comparisons

In the first 90 d after transplantation, there was no
observed difference in the overall (comparing the United
Kingdom with the United States: HR, 0.96; 95% confidence interval [CI], 0.82–1.12; P = 0.63; Table 2, Figure 4)
or disease-specific risk-adjusted mortality (P always >0.05;
Table 2, Figure 4). In contrast, the risk-adjusted overall mortality between 90 d and 1 y was found to be approximately
29% poorer in the United States (comparing the United

FIGURE 2. Time trends in the indications for liver transplant in the United States and United Kingdom between 2008 and 2016. UK,
United Kingdom; US, United States.
Copyright © 2021 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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FIGURE 3. Kaplan-Meier survival graphs by liver disease category for liver transplant recipients in the United States and the United
Kingdom between 2008 and 2016. ALD, alcohol-related liver disease; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; PBC,
primary biliary cholangitis; UK, United Kingdom; US, United States.

Kingdom with the United States: HR, 0.71; 95% CI, 0.59–
0.85; P < 0.001; Table 2, Figure 4) with the poorer mortality
in the United States in this epoch of follow-up time most
clearly in those who underwent LT for HCV (HR, 0.35;
95% CI, 0.19–0.66; P = 0.001). Between 1 and 5 y after LT,
recipients in the United States were again 29% more likely
to have died compared with their UK counterparts (comparing the United Kingdom with the United States: HR, 0.71;
95% CI, 0.63–0.81; P < 0.001). In this epoch of follow-up
time, similar results were observed in those transplanted
for HCC (HR, 0.71; 95% CI, 0.58–0.88; P = 0.002), ALD
(HR, 0.64; 95% CI, 0.45–0.89; P < 0.001), and metabolic
liver diseases (HR, 0.54; 95% CI, 0.30–0.95; P = 0.03). The
corresponding unadjusted and risk-adjusted graft loss hazards are shown in Figure S2 (SDC, http://links.lww.com/TP/
C303) and Table S3 (SDC, http://links.lww.com/TP/C303).
A statistically significant time-dependent country effect
was identified in the overall comparisons of mortality
(P = 0.004) and in those who receive a transplant for HCV
(P < 0.001), which indicates that the differences in posttransplant mortality between the United States and United
Kingdom varied according to the time period after transplantation. The country-specific impact on risk-adjusted
mortality did not differ by era of transplantation (P = 0.38).
DISCUSSION
Summary of Results

Between 2008 and 2016, we found mortality 5 y after
adult first elective LT to be higher in the United States than
in the United Kingdom. The risk of graft loss paralleled
this observed mortality hazard. This was despite only 1 in
16 recipients in the United States receiving a DCD donor
liver compared with 1 in 4 in the United Kingdom. No
significant mortality difference between the countries was

identified in the first 90 d after transplantation, but it was
significantly higher in the United States thereafter.
Comparison With Other Studies

In the only similar study of its kind—and using data
from the same data sets between 1994 and 2005—members of this research group identified that mortality in the
shorter term (0 and 90 d) was significantly lower in the
United States than in the United Kingdom but in the long
term significantly worse (1 y onward).1 It was felt that the
most likely explanation for the observed time-dependent
differences in mortality was the difference in the provision
and quality of care.1 More specifically, they postulated that
the better availability of intensive care beds and superior
nurse–patient ratios translated into lower perioperative
mortality in the United States and a stronger primary care
infrastructure and more equitable access to healthcare into
lower long-term mortality in the United Kingdom.1
Explanation of Results

The poorer longer-term mortality in the United States
may reflect differences in the ability of each country’s
healthcare system to identify and treat disease recurrence.
In the case of HCV, the widespread provision of antivirals in the United Kingdom through their early access
programs24 may have more universally treated early posttransplant HCV recurrence than in the United States and
explain superior outcomes from 90 d to 1 y.
With respect to ALD, a healthcare structure more adept
at monitoring, managing, preventing, and treating the
posttransplant complications25–29 to be expected in those
who have suffered from alcoholism may explain noticeably better survival from 1 to 5 y in the United Kingdom.
Observed higher longer-term posttransplant mortality
in the United States in HCC recipients may not only be
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TABLE 2.

A time-dependent comparison of 5-y patient mortality between the United Kingdom and United States in those
receiving a deceased donor liver transplant
United Kingdom compared with the United States,
hazard ratio (95% CI)
Primary liver disease

Overall
Unadjusted
Adjusteda
HCC
Unadjusted
Adjusted
Hepatitis C
Unadjusted
Adjusteda
PSC
Unadjusted
Adjusteda
Hepatitis B
Unadjusted
Adjusteda
PBC
Unadjusted
Adjusteda
ALD
Unadjusted
Adjusteda
AID
Unadjusted
Adjusteda
Metabolic
Unadjusted
Adjusteda
Others
Unadjusted
Adjusteda

0–90 d

90 d–1 y

1–5 y

P for time
dependency

0.88 (0.76–1.02)
0.96 (0.82–1.12)

0.65 (0.55–0.77)
0.71 (0.59–0.85)

0.66 (0.59–0.74)
0.71 (0.63–0.81)

0.0068
0.004

0.96 (0.71–1.31)
0.88 (0.64–1.21)

0.96 (0.74–1.24)
0.87 (0.66–1.14)

0.79 (0.65–0.96)
0.71 (0.58–0.88)

0.38
0.35

0.60 (0.34–1.06)
0.60 (0.34–1.08)

0.36 (0.19–0.66)
0.35 (0.19–0.66)

1.03 (0.78–1.35)
1.01 (0.76–1.35)

0.002
0.0006

1.08 (0.62–1.86)
1.23 (0.67–2.26)

0.61 (0.25–1.44)
0.69 (0.28–1.72)

0.96 (0.63–1.48)
1.06 (0.64–1.76)

0.52
0.55

1.73 (0.60–4.90)
2.48 (0.72–2.26)

Not enough events
(United Kingdom)
Not enough events
(United Kingdom)

Not enough events
(United Kingdom)
Not enough events
(United Kingdom)

NA
NA

0.65 (0.35–1.23)
0.72 (0.35–1.49)

0.60 (0.28–1.30)
0.66 (0.28–1.55)

0.53 (0.30–0.92)
0.57 (0.30–1.10)

0.88
0.86

0.82 (0.60–1.12)
0.95 (0.68–1.32)

0.71 (0.46–1.10)
0.82 (0.52–1.29)

0.56 (0.41–0.77)
0.64 (0.45–0.89)

0.23
0.21

0.73 (0.43–1.26)
0.79 (0.44–1.35)

0.96 (0.52–1.78)
1.00 (0.53–1.89)

0.53 (0.28–1.00)
0.54 (0.28–1.03)

0.41
0.38

1.08 (0.70–1.66)
1.07 (0.68–1.69)

0.70 (0.37–1.32)
0.68 (0.35–1.30)

0.57 (0.33–0.99)
0.54 (0.30–0.95)

0.19
0.14

1.05 (0.62–1.77)
1.37 (0.75–2.48)

1.59 (0.70–3.59)
2.12 (0.89–5.07)

0.61 (0.32–1.13)
0.82 (0.41–1.65)

0.16
0.18

a

Adjusted for recipient characteristics: sex, age, ethnicity, BMI (kg/m2), disease cause, functional status, ascites, encephalopathy, HCV status, MELD, pretransplant renal replacement therapy,
and previous abdominal surgery and for donor characteristics: sex, age, BMI (kg/m2), CIT, donor type (DCD/DBD), cause of death, ABO match, and graft type.
AID, autoimmune disease; ALD, alcohol-related liver disease; BMI, body mass index; CI, confidence interval; CIT, cold ischemia time; DBD, donation after brainstem death; DCD, donation after
circulatory death; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; MELD, Model for End-Stage Liver Disease; NA, not available; PBC, primary biliary cholangitis; PSC, primary sclerosing
cholangitis.

because of differences in healthcare structure but also
because of differences in tumor characteristics.30,31
The mean annual transplant center volume is significantly lower in the United States. Historically, center
volume has been proven to be a critical (albeit waning)
determinant of outcome.1,32,33 However, in our model,
we felt it unfair to adjust for this parameter as transplant
center volume could reflect the health system organization
and infrastructure that is used by a country to deliver LT
services and therefore help to explain the observed differences in posttransplant mortality. In the United Kingdom,
the centralization of surgical specialties has been shown to
improve postoperative mortality significantly.34 Compared
with the United Kingdom, the United States is known
to have a larger number of transplant centers, most of
which perform a relatively low number of LTs annually.1
However, further analyses (results not shown) that repeat

the comparison of post-LT outcomes between the United
States and the United Kingdom but leave out the 36 smallest centers (centers performing <100 transplants in the
study period)—so that the average volume in the United
States is comparable with that in the United Kingdom—
did not change the pattern of results.
Differences in the selection of recipients and allocation
of donor organs could play a role as well. For example, the
MELD score system was introduced in the United States in
2002 as a guide for recipient selection and organs are allocated within geographic regions.35 In the United Kingdom,
the United Kingdom Model for End-Stage Liver Disease
score was used for patient selection during the study period
and the centers allocate organs offered to them to patients on
their own waiting list.36,37 We included era in the multivariable models as a sensitivity analysis to evaluate for possibly
differential impact on the year of transplant. No statistically
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FIGURE 4. Unadjusted and adjusted hazard ratios (and 95% CI) for mortality in the first 90 d, 90 d to 1 y, and beyond the first year in the
United States (n = 42 874) compared with the United Kingdom (n = 4950) by liver disease category. *Adjusted for recipient characteristics:
sex, age, ethnicity, body mass index (kg/m2), disease cause, functional status, ascites, encephalopathy, HCV status, model of end-stage
liver disease, pretransplant renal replacement therapy, and previous abdominal surgery and for donor characteristics: sex, age, body
mass index (kg/m2), cold ischemic time, donor type (donation after circulatory death/donation after brainstem death), cause of death,
ABO match, and graft type. AID, autoimmune disease; ALD, alcohol-related liver disease; CI, confidence interval; HCC, hepatocellular
carcinoma; HCV, hepatitis C virus; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.

significant difference in the observed mortality hazard was
noted, which was interpreted as the effect of country (United
States versus United States) on posttransplantation mortality
did not vary according to era of transplant.
It is noteworthy that in the United States, recipients
waited considerably longer to receive their LT, but they
received a donor liver that was overall of much higher
quality than in the United Kingdom. However, given that
liver disease severity markers and donor organ quality
were included in our risk adjustment, it is unlikely that differences in donor and recipient characteristics fully explain
observed differences in mortality. Instead, recently demonstrated improvements in short-term posttransplant term
mortality in the United Kingdom may better explain why
compared with our previous comparison of posttransplant
outcome—almost 15 y ago—the United States no longer
has lower 90-d mortality.6 It remains unclear whether the
United States has experienced the same improvements in
shorter-term mortality. Our comparison of international
outcomes suggests that is not the case.
The higher risk-adjusted mortality among US survivors in
the longer term (beyond 90 d) is most likely to be explained
by a genuine difference in the organization and quality of
care.1 These differences between countries may be reflected
in several factors that predict longer-term posttransplant
outcomes, including differences in immunosuppressive strategies and the management of the complications of immunosuppression, disease recurrence, and other comorbidities.1

The provision of and adherence to posttransplant immunosuppression is a strong determinant in the LT beyond the
initial operation.25 In the United Kingdom, lifetime statefunded immunosuppressive medications are provided to
all transplant recipients, where a lack of a coherent funding policy for transplant recipients in the United States has
been postulated as a cause for poorer posttransplantation
outcomes.25,26 For example, the 2016 Commonwealth
Fund International Health Policy Survey found that 1 in
3 adults in the United States forgo medical treatment or
follow-up due to cost-related barriers compared with <1
in 10 adults in the United Kingdom.28
LT recipients are prone to a range of chronic conditions
that include hypertension, hyperlipidemia, new-onset diabetes after transplantation, and cardiovascular disease.29
The better equity of access to “free” healthcare in the
United Kingdom and a strong primary care structure—
all provided under the umbrella of a universal healthcare
system—may be better equipped than the United States to
manage the more chronic complications of LT and thus
further explain longer-term mortality differences.38,39
Methodological Limitations

International comparisons of outcomes come with recognized difficulties.1 For example, differences between
countries in the ascertainment of death could lead to the
systematic underreporting of posttransplant mortality and
artificial estimates of superior survival.40 However, in each
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of the national data sets, well-established processes for
ascertaining death exist.41,42
Despite considerable risk adjustment in our comparison,
it cannot be excluded that observed short- and longer-term
mortality differences can be explained by residual confounding.1 However, our risk adjustment model includes
a wide range of risk factors, so it is unlikely that residual
confounding can fully account for the marked differences
in mortality.1 This is in line with conclusions from a related
study comparing kidney transplant outcomes between the
United States, United Kingdom, and Australasia that specifically aimed to quantify the potential effects of unmeasured confounding.43
Despite the risk adjustments for factors that have previously been demonstrated to represent confounders for
post-LT outcomes, the databases do not contain detailed
information regarding comorbidities, which would
require linking other sources of clinical and administrative databases. A previous analysis of UK transplant data
carried out by members of our research group found
that renal disease, pulmonary disease, and diabetes had
no impact on mortality. In contrast, cardiovascular disease was associated with statistically significantly higher
mortality in all 3 periods after LT (0–90 d, 90 d to 5 y,
beyond 5 y).29 This suggests that if there are differences
between the 2 groups with regards to cardiovascular disease, it may explain some of the differences observed.
An evaluation of the impact and possibly varying effects
across countries of factors such as cardiovascular disease
thus warrants future evaluation. In addition, a number of
factors that may be related to the post-LT outcome were
not available, including medication coverage, detailed
information about comorbidities, geographical distance
to a transplantation center, and socioeconomic status.44
Regarding HCV patients, direct-acting antiviral (DAA)
therapy became widely available in 2014 in the United
States.45 In the United Kingdom, the early access program
of DAA therapy began in 2014.46,47 It is conceivable that
DAA therapy could be a confounding factor in the analysis, mainly if there were differences in the utilization of
such therapy between the countries. Notwithstanding this
potential limitation, given that DAA therapy was introduced at similar times in both countries, and the time in
which their effects could have been exerted is relatively
short in the study period (2014–2016), it is conceivable
that any confounding effect, if present, would likely have
been small. Linkages with other national data sets may
provide these crucial data for further analyses.
Differences in data quality are therefore an unlikely
explanation for the observed differences in mortality. In
both the United States and the United Kingdom, the collection of data on transplant activity is mandated, which
means that they are subject to robust quality assurance
procedures that help to ensure the submission of highly
complete and accurate data, validation, and ascertainment
of posttransplant events. This is well demonstrated by the
low rate of missing data and the many high-quality peerreviewed publications that have originated from data provided by these data sets.
Another limitation of our analysis is that we used predefined posttransplant epochs (up to 90 d, between 90 d and
2 y, and between 2 and 5 y) to investigate the time dependency of the impact of HCC on patient and graft survival.
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This approach assumes that the prognostic impact of HCC
on survival is constant within each of these epochs. The
advantage of this approach is that the HRs can be estimated using standard Cox regression methods and, more
importantly, that the results are relatively easy to interpret.
Its disadvantage is that the partitioning of the survival time
in distinct epochs needs to be chosen in advance and that
the number of separate epochs as well as their duration is
arbitrary.
Implications

There are several implications of this work. First, the
difference in long-term outcomes between LT recipients in
the United States and the United Kingdom highlights the
need for further investigation to clarify factors that may
be responsible for driving these differences. It is possible
that other factors than those directly related to surgery
and immediate perioperative care may contribute to these
differences, which may represent actionable targets for
future quality improvement. In particular, a reappraisal of
the factors related to posttransplant surveillance strategies
may be warranted with an emphasis on patients’ access to
healthcare and immunosuppressive medications.
Second, this study should catalyze future registry development. The reason for this is that, despite the already
well-standardized practice of solid organ transplantation,
differences may exist that may result from exposures that
are not measured, which should be identified to afford
continued global improvements in outcome in LT.
Third, this study demonstrates that an increased emphasis on the use of marginal grafts may be necessary in the
United States as it carries the potential of reducing the time
to transplantation while still maintaining acceptable postLT outcomes. With respect to this, improvements in shortand longer-term outcomes in the United Kingdom, despite
using more marginal grafts, could act as a benchmark, as
could the centralization of their LT services.6,36
Finally, a range of future analyses are necessary to
get a better understanding of the factors that contribute
to the observed time-specific differences in post-LT outcomes between the United States and United Kingdom.
Additional data may be available through linkage with
other national data sets. These future analyses should
focus on differences in the impact that donor and recipient characteristics have on outcomes according to time
after transplantation. It is also important to investigate to
what extent differences in post-LT outcomes between the
United States and the United Kingdom can be explained
by specific differences in the organization and delivery of
transplant services, including recipient selection and organ
allocation, the centers’ annual transplant volume, and the
distance of the recipients’ place of residence to their nearest transplant center.
CONCLUSIONS
Despite the use of better-quality donor organs in the
United States, long-term post-LT mortality outcomes are
worse in comparison with the United Kingdom. Further
detailed investigation of differences in the delivery of and
management after LT in the United States and United
Kingdom may highlight targets for future improvement
efforts to maximize outcomes after LT.
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